What is the current stock price of Artrya Limited?

The current stock price of Artrya Limited is A$3.87, as of the latest trading session on the ASX. It reflects a slight decline of 1.02% recently but substantial annual growth.

How does Artrya use AI in healthcare?

Artrya utilizes AI for the detection of coronary artery disease through its software, Salix, improving diagnosis speed and accuracy in medical imaging.

What is Meyka AI's rating for AYA.AX?

Meyka AI rates AYA.AX with a 'B' grade and a 'HOLD' recommendation, highlighting a balanced evaluation based on various financial and market factors including S&P 500 benchmarks.

What are Artrya's financial challenges?

Artrya faces challenges with negative earnings, as indicated by a PE ratio of -21.89, reflecting ongoing operating losses despite expansive market growth potential.

What future price forecasts exist for Artrya?

Meyka AI forecasts a short-term price target of A$4.44, with expectations to potentially rise to A$21.92 in the long term, indicating significant growth potential.

AU Stocks

AYA.AX Pre-Market (19 Dec 2025): AI Sector Growth Potential

ByHuzaifa Zahoor December 18, 2025December 18, 2025

Artrya Limited (ASX:AYA), a pioneer in AI-powered healthcare solutions, is capturing significant attention. Despite its current price dip to A$3.87—down by 1.02% in recent trade—the company remains a potential standout in AI-driven healthcare innovation.